Video: “Active Surveillance Decisions”

November 2019 Awareness Night Active Surveillance Decisions (Why, Who, How, and When you know it’s time to be treated) Dr. Danny Vesprini, MD, MSc, FRCPC Affiliate Scientist, Biological Sciences, Odette Cancer Research Program, Sunnybrook Research Institute Radiation Oncologist, Dept. of Radiation Oncology, Sunnybrook Odette Cancer Centre Asst. Prof., Dept. of Radiation Oncology, U. of Toronto     CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 1:04:57 minutes <

New Incision-Free Ultrasound Treatment for Prostate Cancer Unveiled

A new study of this pioneering new approach uses sound waves to heat and destroy tumors and leaves the healthy surrounding tissue untouched according to Science Daily. This minimally invasive method that is called MRI-guided transurethral ultrasound ablation (TULSA) relies on a rod-shaped device that is inserted directly into the urethra and are controlled by a software algorithm. What’s even more remarkable is that the entire procedure — called Tulsa-pro – is done in an MRI scanner and not in an operating room. This treatment is not available in North America at present. Read the article.

Gleason 6 Is Bogus Prostate Cancer

Noted urologic surgeon Bert Vorstman, MD, MS, FAAP, FRACS, FACS today has issued a stinging report regarding the unreliable PSA test, the mislabeling of the common Gleason 6 prostate disease as a cancer, and the misrepresentation that the radical (robotic) prostatectomy treatment is scientifically proven to be safe and effective – a charade that represents an outrageous and shameful trifecta of abominations. Read the article.

Age-related risks of radical prostatectomy

It will hardly come as a surprise to most prostate cancer support group leaders and other prostate cancer advocates that there is a strong association between patient age and risk for side effects of radical prostatectomy. However, we now have a rather more sophisticated set of insight into such risks. Read the article.

Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.

Data from the survival outcomes of patients support the use of active surveillance in low risk and intermediate risk cases of Gleason 6 but not Gleason 7 prostate cancer. Multiparametric magnetic resonance imaging and novel biomarkers might be vital in detecting favorable Gleason 7 disease. Read the article here.

Scroll to Top